Withus Pharmaceutical Co

Withus Pharmaceutical Co FCF per Share

The Free Cash Flow per Share of Withus Pharmaceutical Co (330350.KQ) as of Nov 1, 2026 is 277.77 KRW. In the previous year, Free Cash Flow per Share was 232.37 KRW — a change of 19.54% (higher).

FCF per Share

277.77KRW

YoY

19.54%

Last updated:

Free Cash Flow per Share of Withus Pharmaceutical Co is 2025 277.77 KRW. Free Cash Flow per Share of Withus Pharmaceutical Co was 2024 232.37 KRW. It decreases by 19.54% higher compared to the previous year.

The Withus Pharmaceutical Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
413.20 KRW
Jan 1, 2019
246.90 KRW
Jan 1, 2020
-337.76 KRW
Jan 1, 2021
102.71 KRW
Jan 1, 2022
-754.51 KRW
Jan 1, 2023
-1,003.66 KRW
Jan 1, 2024
232.37 KRW
Jan 1, 2025
277.77 KRW
The Withus Pharmaceutical Co FCF per Share history
YEARFCF per ShareYoY
277.77KRW+19.54%
232.37KRW-123.15%
-1,003.66KRW+33.02%
-754.51KRW-834.63%
102.71KRW-130.41%
-337.76KRW-236.80%
246.90KRW-40.25%
413.20KRW+13.01%
365.63KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Withus Pharmaceutical Co Stock analysis

What does Withus Pharmaceutical Co do? Withus Pharmaceutical Co Ltd is a pharmaceutical company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on the manufacturing and distribution of prescription drugs, with its headquarters located in Seoul. As of the latest available information, Withus Pharmaceutical employs 191 full-time staff members. The company completed its initial public offering (IPO) on July 3, 2020, marking its entry into the public market. Its primary product categories include circulatory agents, musculoskeletal agents, digestive agents, antibiotics, and other prescription medications. Additionally, the company engages in contract manufacturing operations (CMO), providing manufacturing services for other pharmaceutical entities. Withus Pharmaceutical maintains a corporate website at https://www.withuspharm.com/mastart/mastart.php, which serves as a platform for company information and updates. The company operates in the pharmaceutical industry, contributing to the production and supply of essential medications in South Korea. Withus Pharmaceutical's business model integrates both direct product sales and contract manufacturing services, supporting its role in the broader healthcare ecosystem. The company's operations are centered around the development and delivery of prescription drugs, with a focus on key therapeutic areas such as cardiovascular health, musculoskeletal conditions, gastrointestinal treatments, and infectious disease management. The firm's activities are conducted under the regulatory framework of South Korea's pharmaceutical industry, adhering to local standards for drug manufacturing and distribution. Withus Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Withus Pharmaceutical Co stock

Free Cash Flow per Share of Withus Pharmaceutical Co is 277.77 KRW in 2025.

Free Cash Flow per Share of Withus Pharmaceutical Co changed from 232.37 KRW to 277.77 KRW, representing a 19.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Withus Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Withus Pharmaceutical Co

All Key Metrics — Withus Pharmaceutical Co